Phase 4 N=186 A Treatment for Severe Inflammatory Acne Subjects
Acne Vulgaris
Primary: Change in Number of Inflammatory Lesions — -30.1 Inflammatory lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=201 ABSORICA in Patients With Severe Recalcitrant Nodular Acne
Acne
Primary: Active Treatment Period: Total Acne-Specific Quality of Life Score at Week 20 — 100.7 score
Phase 2 N=257 Treatment of Moderate to Severe Facial Acne Vulgaris
Acne Vulgaris
Primary: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population — 14.1; 15.4; 29.5; 16.4 Percentage…
Phase 4 N=286 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
Acne Vulgaris
Primary: Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12 — 69.7; 81.4 Percentage of participants
Phase 3 N=459 Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris
Severe Acne Vulgaris
Primary: Percent Change From Baseline in Total Lesion Counts at Week 12. — -64; -41 % of change
Phase 3 N=266 Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
Acne
Primary: The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements — 85; 73 count of participants
Phase 3 N=925 Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
Severe Nodular Acne
Primary: Co-primary Outcome 1: Change From Baseline in Total Nodular Lesion Count (Facial and Truncal) — -17.01; -16.52 Lesions — p=0.5077
Phase 2 N=150 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne
Acne Vulgaris
Primary: Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment — 16; 14.58; 11.54 Percentage of…
Phase 4 N=171 Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts (Papules,Pustules, and Nodules) at Week 12 — 38.94; 40.78; -25.77; -24.82 Number of Lesions
N/A N=72 Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia
Skin Lesion · Skin Abnormalities · Sebaceous Hyperplasia
Primary: Total Number of Cleared SH Lesions — 99.5 Percentage of cleared SH Lesions
Phase 2 N=68 A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
Acne Vulgaris
Primary: Change in Inflammatory Lesions With Daily Use of NAG Compared With Vehicle After 12-weeks of Use. — -27; -44 % change of inflammatory lesions count — p=<0.01
Phase 4 N=22 The Use of Oracea and Epiduo Forte in Severe Acne Patients
Acne
Primary: Investigator Global Assessment (IGA) Score — 0; 0; 20; 0 Participants
Phase 2 N=285 Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
Acne Vulgaris
Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at the Final Visit — 12.8; 14.4; 17.6; 17.1 Number of Inflammatory Lesions — p=0.4344
Phase 1 N=10 A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Successful Engraftment of Probiotic Following a Single Application. — 2; 1 Participants
Phase 1 N=36 A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne
Acne Vulgaris
Primary: Number of Participants With Changes in Local Skin Reactions — 19; 11; 2; 1 Participants
Phase 3 N=550 A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions
Phase 2 N=40 Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
Acne Vulgaris
Primary: Total Lesion Count (Inflammatory and Non-inflammatory) — 23.57; 32.90 Lesions — p=<.001
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008
Phase 2 N=294 Efficacy Study in Patients With Acne Vulgaris.
Acne Vulgaris
Primary: Percent Change From Baseline to Week 12 in the Inflammatory (Papules and Pustules) Lesion Counts on the Face — -60.84; -62.17 percentage change in lesion counts — p=0.5947
Phase 3 N=547 A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 29.4; 29.7; 15.9; 18.2 Lesions
Phase 4 N=23 Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients
Acne Vulgaris
Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale
Phase 4 N=28 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted
Phase 2 N=22 Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
Actinic Keratosis
Primary: PGA Score — 0.53 score on a scale
Phase 2 N=213 P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Absolute Change in Inflammatory Lesion Counts — -7.7; -4.1; -11.2; -11.3 inflammatory acne lesions
Phase 4 N=163 Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts (Papules, Pustules and Nodules) at Week 12 — 38.96; 40.06; -24.05; -25.82 Number of Lesions
N/A N=10 Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Number of Inflammatory Lesions (Papules and Pustules) — 6; 3; 10; 0 Lesions
Phase 2 N=3 Afamelanotide in Patients Suffering With Acne Vulgaris
Acne Vulgaris
Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions
Phase 4 N=67 Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Acne Vulgaris · Atrophic Acne Scars
Primary: Part 1: Total Atrophic Acne Scar Count Per Half-face — 9.5; 13.3 atrophic acne scars — p=<0.0001
Phase 2 N=18 Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel
Acne Vulgaris
Primary: Change From Baseline in Inflammatory Lesion Counts at Week 12 — 22.3; 19.0 inflammatory lesions
N/A N=34 Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
Acne
Primary: Level of IL-1β — 52.5; 361.2 pg/mg